Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 23, 2003 Jeff Hwang	Bad, Bad Baxter The medical products company issues its latest in a series of earnings warnings.
The Motley Fool April 22, 2005 Brian Gorman	Baxter Is on the Mend The medical products company continues to right itself for a brighter future. The firm's long-term positioning and diversified business may make it worth a closer look.
The Motley Fool April 20, 2006 Stephen D. Simpson	Baxter Bags Better Margins This is a great business -- but only at the right price. Investors, this story has to be bought cheap. At today's prices, is it cheap enough?
The Motley Fool July 20, 2007 Brian Orelli	Baxter's Mixed Message A recall of Baxter BioScience's COLLEAGUE infusion pumps seems to have over-shadowed healthy quarterly earnings reports.
Chemistry World March 28, 2014 Phillip Broadwith	Baxter aims to divide and conquer US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies.
The Motley Fool October 16, 2009 Robert Steyer	Baxter Beats Again -- the Streak Is Alive! The drug, device, and medical services giant beats Wall Street earnings estimates by a penny, but flat sales signal caution.
The Motley Fool April 17, 2009 Robert Steyer	The Steady BAX Beat Baxter International's diverse medical offerings continue to produce prosperity.
The Motley Fool July 25, 2007 Brian Orelli	Hopeful Flu Production Technology From Baxter While the clinical trial demonstrating strong immunogenicity for the new vaccine is certainly good news, the continued development of the production technology is probably the more important item for investors.
The Motley Fool January 26, 2005 Brian Gorman	Kraft's Problem Area International operations have to be high on the company's list as it seeks to improve its performance.
The Motley Fool April 18, 2008 Brian Orelli	Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter.
The Motley Fool February 25, 2004 Mark Mahorney	Don't Shortchange the Dollar What you need to know about the dollar and investing in foreign companies. If you're investing in multinational or foreign companies, you might be a daredevil currency speculator and not even know it. Here's what you need to know -- and likely aren't being told -- about the effect of currency fluctuations on your investments.
The Motley Fool November 3, 2011 Dan Caplinger	Has Baxter International Become the Perfect Stock? Baxter needs to keep working on getting its debt levels down and seek out new growth opportunities. With favorable demographic winds at its back, Baxter could be the rare stock to actually reach perfection.
The Motley Fool October 19, 2007 Brian Orelli	Baxter Gets Pumped Up Medical-device maker Baxter puts in a nice quarter despite two recent FDA recalls.
Knowledge@Wharton	The Future of the Euro-Dollar Relationship Depends a Lot on the U.S. Depending on how it is accepted, the euro could ultimately become an alternative to the dollar as a global reserve currency and provide a place of refuge if mounting U.S. debt finally leads to a weaker dollar, according to international finance experts...
The Motley Fool August 30, 2007 Brian Orelli	Forget What Your Drug Was Approved For Baxter stages a new trial for an old drug.
The Motley Fool September 24, 2008 Brian Orelli	Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days.
CIO October 28, 2011 Kim S. Nash	Why Legal Concerns Put a Halt to BYOT at Baxter Baxter International wanted to allow employees to bring their own devices to work, but legal concerns related to e-discovery had to be resolved first.
The Motley Fool January 23, 2009 Robert Steyer	BAX to the Future After minding its own business, Baxter International starts thinking about acquisitions again.
The Motley Fool August 31, 2011 Harsh Chauhan	Medtronic Looks Set for Takeoff Medtronic shares jump after flat quarterly growth as it looks toward global expansion.
The Motley Fool August 20, 2007 Brian Orelli	Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign.
The Motley Fool February 29, 2008 Brian Orelli	Bigger Recall, No Big Deal Baxter increases its recall of heparin, but investors shouldn't be that worried.
Fast Company April 2004 Keith H. Hammonds	Moment of Truth? It has been a tortuous year for Harry M. Jansen Kraemer Jr., CEO of Baxter International Inc. Back in November 2002, we lauded Kraemer's forthright leadership as his company confronted the deaths of 53 patients due to contaminated dialysis filters made by a Baxter subsidiary. Now Kraemer is out of a job.
The Motley Fool September 27, 2007 Billy Fisher	Baxter Looking to Bounce Back Shares of the medical device maker finally rebound following a company recall of infusion pumps.
The Motley Fool April 26, 2010 Jennifer Schonberger	The S&P 500's Biggest Movers Meet the index's major players for the past week.
BusinessWeek November 29, 2004 Ewing & Cohn	Beware The Brawny Euro As it strengthens, Europe's currency threatens to snuff out a tenuous recovery.
The Motley Fool May 20, 2009 Dan Caplinger	Is Now the Time for Currency ETFs? If you want to protect yourself against a dollar decline, exchange-traded funds based on the values of various foreign currencies make it easy.
The Motley Fool January 25, 2008 Brian Orelli	Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that.
Insurance & Technology September 5, 2006 Maria Woehr	Thrilling Service To maintain its dominant position in Maine's worker's compensation market, Maine Employer's Mutual Insurance Company leverages IT to improve service for its agent customers.
The Motley Fool February 1, 2005 Nathan Slaughter	Is Fuel Sinking Royal Caribbean? The cruise line reports a wider fourth-quarter loss and missed estimates.
The Motley Fool October 20, 2005 Stephen D. Simpson	Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock.
The Motley Fool March 7, 2008 Brian Lawler	A Little Too Much Drug Variability Another drugmaker has to recall batches of its compound.
The Motley Fool April 10, 2008 Brian Orelli	The News for Baxter Just Got Worse These heparin-related deaths aren't associated with Baxter's product, but they still might spell trouble for the company.
The Motley Fool October 20, 2009 Brian Orelli	Pfizer Starts the Blame Game Pfizer beat analysts' expectations for both revenue and adjusted earnings, but revenue was still lower than the year-ago quarter. Pfizer has excuses.
Finance & Development March 1, 2007 Bertuch-Samuels & Ramlogan	The Euro: Ever More Global The euro's future use will be shaped by factors largely outside policymakers' control.
The Motley Fool October 19, 2005 Stephen D. Simpson	ICU, You Look Healthier An incredible third quarter shows what operating leverage can do for this little medical technology company. Investors, take note.
Registered Rep. June 14, 2007 Kevin Burke	Pilgrim Baxter's Payback The SEC announced this week that it is returning ill-gotten gains to Pilgrim Baxter (investment advisor to the PBHG fund family) shareholders, three and half years after the fund company was engulfed in a trading scandal.
HBS Working Knowledge September 29, 2003 Michael Sisk	Do the Right Thing How does a commitment to "do the right thing" as it's applied to customers, employees, and other stakeholders affect an organization's daily decision making?
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
Finance & Development March 1, 2002 Kenneth S. Rogoff	The Surprising Popularity of Paper Currency Will the global underground economy be the prime destination for those large euro notes?
Financial Advisor August 2006 Eric Uhlfelder	Profiting From Foreign Exchange Currency exposure can add diversification and gains to portfolios -- if you're careful. Financial advisors should understand from the start that exchange rate movements are notoriously difficult to forecast over the near term.